MicroTransponder Presents Long Term Stroke Trial Data at INS and Announces a 120 Patient Pivotal Stroke Trial

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following two offers if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+1 year archive
Canadian Market INK weekly newsletter
+1 year archive
3 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
No requirement to accept commercial emails from us
30-day money back guarantee*
JOIN THE CLUB
Canadian Insider Ad-Free
$49/ year*
All benefits of basic registration
No 3rd party display ads
No requirement to accept commercial emails from us
30-day money back guarantee*
GO AD-FREE

* Price is subject to applicable taxes. Money back guarantee: For bona fide Ad-Free or Canadian Insider Club subscribers, if you cancel with-in 30 days of first subscribing, we will refund your payment upon request. After cancelling, using the same email that is associated with your account, request a refund via our Contact Us form at the bottom of the page. We will only consider one refund request per household or organization. We cannot accommodate refund requests where an account holder has not provided verifiable address and billing information.

MicroTransponder Presents Long Term Stroke Trial Data at INS and Announces a 120 Patient Pivotal Stroke Trial

Late Breaking Long Term Clinical Study Results at the International Neuromodulation Society Conference Show Continued Improvement for Stroke Patients and a New 120 Patient Stroke Trial Will Begin Enrollment this Summer

DALLAS, TX--(Marketwired - May 30, 2017) - MicroTransponder, Inc., (www.microtransponder.com) today unveiled new positive long-term positive clinical trial results from the Vivistim™ Stroke Rehabilitation trial. The objective of this multicenter, double-blind, randomized, active-controlled trial was to improve upper limb mobility in stroke survivors suffering chronic disability. The data was presented by Jesse Dawson M.D., University of Glasgow Hospital, and Teresa Kimberley, PhD, University of Minnesota Hospital. They presented the data to the clinicians gathered at the International Neuromodulation Society (INS) conference in Edinburgh, UK. The data showed 75% of patients had a clinically meaningful response on the Fugl-Meyer Upper Extremity Scale (FMUE) at the end of a six weeks of physical therapy compared to 33% for the control group. 90 days after the six weeks of physical therapy ended 88% of VNS patients had responded compared to 33% in the control arm. And during the long-term portion of the study average FMUE scores continued to increase, with the 6 month and 9 month data showing further gains. All responders indicated they believed their overall health had improved and were satisfied with the therapy.

"We saw remarkable improvement in some patients' upper limb function over the course of this trial," said Dr. Dawson. "For many patients, this included important daily activities such as feeding, grooming, driving, and dressing themselves. Some patients were able to resume their higher-level hobbies, such as photography, practicing piano, hosting large family events, and playing golf. Overall, my patients were able to integrate the at- home-therapy component of the program quite easily into their lives."

The Stroke Rehabilitation trial featured the Vivistim® System, which is a neurostimulation based system with a small implanted battery and wires that internally connect to the vagus nerve in the neck. As the patient performs physical therapy exercises, they receive a small burst of neurostimulation to their vagus nerve. This Paired VNS® (Vagus Nerve Stimulation) method is based on decades of neuroscience research and takes advantage of the brain's ability to rewire itself (neuroplasticity). When stimulated, the vagus nerve causes the release of neurochemicals in the brain that encourage neuroplasticity. More information can be found on www.MicroTransponder.com.

In addition to the presentation of the long-term data, Frank McEachern, CEO of MicroTransponder; also spoke at the INS. McEachern announced that MicroTransponder had received IDE approval from the FDA to run a 120-patient pivotal trial. The stroke rehabilitation trial will include 12 U.S. and 3 UK centers and will begin enrolling patients this Summer. "There are currently very few options for chronic stroke survivors and our committed team of physicians, researchers, and engineers hope to deliver a meaningful option that will make a significant difference for these survivors and their families," noted McEachern. "We experienced an outpouring of interest from many academic centers to participate in our clinical trials once we presented our initial stroke rehabilitation data at the International Stroke Conference earlier this year. We are pleased to announce that our 120-patient clinical trial is now approved and includes many prestigious institutions and some of the best stroke and neurostimulation researchers worldwide. Enrollment will begin this Summer and additional clinical trial information can be found by visiting www.vnsstroketrial.com."

About MicroTransponder, Inc.

MicroTransponder Inc. (www.microtransponder.com) is a medical device development company with a strong neuroscience research focus. An experienced team of scientists and engineers has developed neurostimulation technology platforms to treat various forms of neurological diseases, including post stroke motor rehabilitation and tinnitus. MicroTransponder has a sizeable neurostimulation-focused R&D program which is able to quickly translate scientific discoveries into clinical therapies.

Jordan Curnes
jordan@microtransponder.com
469-225-9268

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).